Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG CLASS:

Osteoclast inhibitor

DRUG CLASS:

Osteoclast inhibitor

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Related drugs:

‹

zoledronic acid (5)

ibandronate sodium hydrate (1)

pamidronate disodium (0)

zoledronic acid (5)

ibandronate sodium hydrate (1)

pamidronate disodium (0)

›

No biomarker	Multiple Myeloma	No biomarker	Multiple Myeloma	zoledronic acid Sensitive: A1 - Approval zoledronic acid Sensitive : A1	zoledronic acid Sensitive: A1 - Approval zoledronic acid Sensitive : A1
No biomarker	Prostate Cancer	No biomarker	Prostate Cancer	zoledronic acid Sensitive: A1 - Approval zoledronic acid Sensitive : A1	zoledronic acid Sensitive: A1 - Approval zoledronic acid Sensitive : A1
No biomarker	Breast Cancer	No biomarker	Breast Cancer	zoledronic acid Sensitive: A2 - Guideline zoledronic acid Sensitive : A2	zoledronic acid Sensitive: A2 - Guideline zoledronic acid Sensitive : A2
No biomarker	Breast Cancer	No biomarker	Breast Cancer	ibandronate sodium hydrate Sensitive: A2 - Guideline ibandronate sodium hydrate Sensitive : A2	ibandronate sodium hydrate Sensitive: A2 - Guideline ibandronate sodium hydrate Sensitive : A2
ER positive	HER2 Negative Breast Cancer	ER positive	HER2 Negative Breast Cancer	zoledronic acid Resistant: C3 – Early Trials zoledronic acid Resistant : C3	zoledronic acid Resistant: C3 – Early Trials zoledronic acid Resistant : C3
NF1 deletion	Breast Cancer	NF1 deletion	Breast Cancer	zoledronic acid Sensitive: D – Preclinical zoledronic acid Sensitive : D	zoledronic acid Sensitive: D – Preclinical zoledronic acid Sensitive : D